Podofilox

Podofilox

SCHEMBL42243

COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

IGF1R

The experimentally established mechanism targets of Podofilox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 1.00
CYP3A4 P08684 6/20 1.00
TUBB4A P04350 5/20 1.00
TUBB P07437 5/20 1.00
TUBA3C P0DPH7 5/20 1.00
TUBA1B P68363 5/20 1.00
TUBA4A P68366 5/20 1.00
TUBB4B P68371 5/20 1.00
TUBB3 Q13509 5/20 1.00
TUBB2A Q13885 5/20 1.00
TUBB8 Q3ZCM7 5/20 1.00
TUBA3E Q6PEY2 5/20 1.00
TUBA1A Q71U36 5/20 1.00
TUBA1C Q9BQE3 5/20 1.00
TUBB6 Q9BUF5 5/20 1.00
TUBB2B Q9BVA1 5/20 1.00
TUBB1 Q9H4B7 5/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
CYP2C9 P11712 2/20 1.00
MAPK1 P28482 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Podofilox SCHEMBL12377923 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Podofilox SCHEMBL30947382 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Podofilox SCHEMBL10005569 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Podofilox SCHEMBL13663652 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Podofilox SCHEMBL10046308 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Epipodophyllotoxin SCHEMBL5792464 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Podofilox SCHEMBL24049951 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Podofilox SCHEMBL13661743 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Podofilox SCHEMBL20807187 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Axl-1717 SCHEMBL29358347 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 41377 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746898-A2 IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2026-05-27 EP claimed
CN-122075734-A Conjugates comprising tetrapeptides, methods of making, intermediates and uses thereof 2026-05-26 CN claimed
CN-118001240-B Podophyllotoxin-9-fluorenylmethanol small molecule prodrug nanoparticle and preparation method and application thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2026-05-26 CN claimed
US-20260139860-A1 PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS CENTRE FOR DIGESTIVE DISEASES (AU) 2026-05-21 US claimed
EP-4094767-B1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-20 EP claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
WO-2026098621-A1 ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF 百力司康生物医药(杭州)有限公司 2026-05-15 WO claimed
WO-2026102168-A1 FIRST-LINE COMBINATION THERAPY WITH PLINABULIN FOR TREATING SMALL CELL LUNG CANCER BEYONDSPRING PHARMACEUTICALS, INC. (US) 2026-05-15 WO claimed
CN-122039325-A Marine wound first-aid bionic composite nanofiber membrane based on mussel adhesive protein and preparation method and application thereof 长岛县长山海珍品有限责任公司 2026-05-15 CN claimed
CN-122031756-A Functional gel dressing for preventing cervical cancer and HPV infection and preparation method thereof 暨南基因再生医疗科技(海南)有限责任公司 2026-05-15 CN claimed
EP-0218300-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-04-15 EP claimed
EP-0207124-A1 Use of podophyllotoxin and derivatives thereof. CONPHARM AB (SE) 1987-01-07 EP claimed
CN-85109666-A Preparation contains the method for pharmaceutically active compounds 1986-10-29 CN claimed
EP-0197219-A1 Process for the isolation and purification of podophyllotoxin Pharma-medica a-s (DK) 1986-10-15 EP claimed
WO-1986004062-A1 PHARMACEUTICALLY ACTIVE COMPOUND AND A METHOD FOR ITS PREPARATION CONPHARM AB (SE) 1986-07-17 WO claimed
EP-0174810-A2 Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein DNA HSC Research Development Corporation (CA) 1986-03-19 EP claimed
EP-0119852-A1 Podophyllotoxin preparations for use in the treatment of genital warts Pharma-medica a-s (DK) 1984-09-26 EP claimed
EP-0110955-A1 BRAIN-SPECIFIC DRUG DELIVERY. UNIV FLORIDA (US) 1984-06-20 EP claimed
WO-1983003968-A1 BRAIN-SPECIFIC DRUG DELIVERY UNIVERSITY OF FLORIDA (US) 1983-11-24 WO claimed
WO-1980000791-A1 B-GLUCURONIDASE ACTIVITY AND/OR PH-DEPENDENT PHARMACEUTICALS AND THEIR METHODS OF PRODUCTION AND USE FOR SELECTIVE TREATMENT OF DISEASES SCHWIMMER A (US) 1980-05-01 WO claimed